November 9, 2023

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

Kiora Pharmaceuticals provided an update on their plans to advance the clinical development of their experimental drug KIO-301 for inherited retinal diseases. They reported results from the ABACUS-1 study, a Phase 1b trial of KIO-301 in patients with late-stage retinitis pigmentosa (RP). The study showed that KIO-301 is safe and tolerable, with significant improvements in visual field and visual function.

Based on these findings, Kiora will expand the clinical development of KIO-301 to include a Phase 2 trial (ABACUS-2) in RP patients, starting in the first half of 2024. 

What this means for Usher syndrome: While the focus is on RP, the successful development of KIO-301 shows promise for treating inherited retinal diseases. The advancements in KIO-301 could lead to therapies targeting the genetic causes of retinal degeneration in Usher Syndrome.

Link to original article

Disclaimer: The information contained on the Usher Syndrome Coalition website and other online properties is provided for your information only. The Coalition is neither a medical service nor a scientific organization. It provides information concerning the various types of Usher syndrome that includes information developed or derived from unrelated third parties over which the Coalition has no involvement or control. The Usher Syndrome Coalition does not independently, nor in conjunction with others, attest to, deny, or comment upon the merits of the accuracy of the information provided by unrelated third parties. No reliance on medical or scientific information contained on this website should be taken by any person. You should always consult with and be guided by your Physician’s advice when considering treatment based on research results.